Document is current
Any future updates will be listed below
-
Authors
Furube, Tasuku
Takeuchi, Masashi
Kawakubo, Hirofumi
Noma, Kazuhiro
Maeda, Naoaki
Daiko, Hiroyuki
Ishiyama, Koshiro
Otsuka, Koji
Sato, Yoshihito
Koyanagi, Kazuo
Tajima, Kohei
Garcia, Rodrigo Nicida
Maeda, Yusuke
Matsuda, Satoru
Kitagawa, Yuko
- License Information
-
More Information
Article History
First Online: 1 October 2024
Disclosures
: Yuko Kitagawa reports grants and personal fees from Asahi Kasei Pharma Corporation; grants, personal fees, and others from Ono Pharmaceutical Co., Ltd; grants and personal fees from Otsuka Pharmaceutical Factory, Inc.; grants and personal fees from Nippon Covidien Inc.; grants, personal fees, and others from Taiho Pharmaceutical Co., Ltd; grants, personal fees, and others from Chugai Pharmaceutical Co., Ltd; grants and personal fees from Kaken Pharmaceutical Co., Ltd; personal fees from AstraZeneca K.K.; personal fees from Ethicon Inc.; personal fees from Olympus Corporation; personal fees from Shionogi & Co., Ltd; personal fees from Bristol-Myers Squibb K.K.; personal fees from MSD K.K.; personal fees from Smith & Nephew KK; personal fees from Aska Pharmaceutical Co., Ltd; personal fees from Miyarisan Pharmaceutical Co., Ltd; personal fees from Toray Industries, Inc.; personal fees from Daiichi Sankyo Company, Ltd; personal fees from Chugai Foundation for Innovative Drug Discovery Science; personal fees from Nippon Kayaku Co., Ltd; grants from Yakult Honsha Co., Ltd; grants from Tsumura & Co.; grants from Sumitomo Pharma Co., Ltd; grants and personal fees from EA Pharma Co., Ltd; grants from Eisai Co., Ltd; grants from Kyowa Kirin Co., Ltd; grants from Medicon Inc.; grants from Takeda Pharmaceutical Co., Ltd; grants from Teijin Pharma Ltd; and personal fees from Intuitive Surgical G.K., outside the submitted work. Yuko Kitagawa and Yusuke Maeda have equity for Direava inc. Masashi Takeuchi is chief Executive Officer for Direava inc. Tasuku Furube, Hirofumi Kawakubo, Kazuhiro Noma, Naoaki Maeda, Hiroyuki Daiko, Koshiro Ishiyama, Koji Otsuka, Yoshihito Sato, Kazuo Koyanagi, Kohei Tajima, Rodrigo Nicida Garcia, and Satoru Matsuda have no conflicts of interest to declare that may be relevant to the contents of this article.
